SLU-PP-915 vs. SLU-PP-332: Why Oral Delivery Changes the Research

A compound can have an impressive mechanism and still face a basic limitation: getting enough of it into circulation through the intended route.

That is why SLU-PP-915 deserves attention alongside SLU-PP-332. My view is that 915 represents a meaningful step forward for oral ERR research. The reason is delivery—not proof that it outperforms 332 in every setting.

Both are experimental small molecules, not peptides. They activate estrogen-related receptors: ERRα, ERRβ and ERRγ. These are distinct from the conventional estrogen receptors.

ERRs help regulate cellular energy programs, including mitochondrial function and the use of fuel. The original SLU-PP-332 research demonstrated increased respiration in muscle cells and improved endurance in mice. ERRα was important to that endurance response.

In the newer comparison, researchers describe 332 as lacking oral bioavailability. SLU-PP-915 is chemically distinct and demonstrated oral activity in mice.

That matters because an effect after administration into the abdominal cavity does not establish that swallowing the compound will reproduce it. A capsule is a dosage form; it is not evidence of absorption or efficacy.

In the mouse experiments, 915 and 332 improved running performance to a similar extent when administered intraperitoneally. Oral 915 maintained comparable efficacy when systemic exposure was accounted for.

The advance was retaining activity through oral delivery. The study did not establish that 915 produces greater endurance gains than 332 across the board.

For researchers investigating an orally administered ERR agonist, demonstrated oral activity is a practical advantage. It makes 915 a more compelling candidate for that particular research question.

The investigators also observed enhanced exercise-associated and mitochondrial gene responses when 915 was combined with training. That is an interesting interaction to investigate, not evidence that a compound replaces exercise.

Better suited to oral research does not automatically mean safer, better for fat loss, or suitable for long-term use. Nor does it establish human oral bioavailability.

Commercial products also cannot be assumed to reproduce a study formulation. Human trials and product-specific evidence would be needed to answer those questions.

SLU-PP-332 helped establish the potential of targeting ERRs. SLU-PP-915 addresses a major delivery limitation while retaining exercise-capacity activity in mice.

That is a meaningful development. The strongest case for 915 is a better tool for oral research—not an established recommendation for personal use.

— Beardedmuscle Facts Over Feelings.